Biotechnology
GMP cell CDMO I Peace, Inc. in collaboration with universities successfully converted human dermal fibroblasts into oligodendrocyte by direct reprogramming
PALO ALTO, Calif., Sept. 20, 2022 /PRNewswire/ -- Koji Tanabe of I Peace, Inc. (
https://www.ipeace.com
2022-09-21 05:39
1169
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tr...
2022-09-20 19:25
1449
Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day
WUHAN, China and SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- September 19th is International LHON Awareness Day. LHON is a debilitating disease that leads to quick vision loss concomitantly or successively. It mostly impacts young adolescent males and brings tremendous physical and psychological st...
2022-09-19 20:00
2378
Taiwan's Anyong Biotechnology First To Employ Seafood Stem-Cell Freezing
KAOHSIUNG, Taiwan, Sept. 19, 2022 /PRNewswire/ -- Anyong Biotechnology, the world-class aquatic food processing company based inTaiwan, is now the first company in the region to employ Cells Alive System (CAS) technology fromJapan. It ranks as the most advanced freezing technology inAsia and is a...
2022-09-19 16:20
1380
New treatment for rare cancer cholangiocarcinoma approved in Australia
* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...
2022-09-15 21:00
1497
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...
2022-09-15 17:07
1380
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment ...
2022-09-14 20:30
2474
DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY
AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft
tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the
appointment of award-winning medical researcher and inventor, Dr.Catherine Mohr
as a Non-Executive Director to the board.
2022-09-14 13:05
1288
MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD
Anderson Cancer Center
2022-09-14 11:09
1238
GBB Lands USD 15M Pre-Series B Funding Led by Tiger Jade Capital
HONG KONG, Sept. 13, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") is pleased to announce today the completion of itsUSD 15M Pre-series B funding led by Tiger Jade Capital (hereinafter referred to as "Tiger Jade"). The funding was oversubscribed and upsized with participat...
2022-09-14 09:08
1795
EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"
* An expert from Invitae and Ambry Genetics, U.S. genome analysis companies * EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" * Worked in a non-profit research orga...
2022-09-13 21:00
1600
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...
2022-09-13 20:00
2211
Origin Agritech Announces Addition to Two FTSE Russell Equity Indices
BEIJING, Sept. 12, 2022 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that effectiveSeptember 16, 2022, Origin Agritech will be added two new equity indices, the FTSE Micro Cap Index and the FTSE Total Cap Index...
2022-09-12 20:45
2246
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
* Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients * For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% * Lemzoparlimab does not require priming ...
2022-09-10 21:00
1914
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosag...
2022-09-09 20:00
1774
Antengene to Present at Upcoming Industry Conferences
SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...
2022-09-09 14:43
1309
InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer
NANJING, China, Sept. 7, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal study ...
2022-09-08 08:00
1652
Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board
NEWARK, Del., Sept. 7, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global R&D biotechnology company, today announced the appointment ofRakesh Dixit , Ph.D., DABT to its Advisory Board to advance Antibody Drug-Conjugates (ADCs) for the treatment of solid tumor cancers in Biosion's pipeline. ...
2022-09-07 20:54
2885
Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study
SHANGHAI and WARREN, N.J., Sept. 6, 2022 /PRNewswire/ -- Laekna, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide, announced yesterday that the first patient recently received a dose in the LAE201INT2101 phase ...
2022-09-06 17:02
1893
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives
CHENGDU, China, Sept. 5, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. ("Unison") are pleased to announce a research collaboration on an undisclosed bacterial target. Under the terms of the agreement, Vernalis will use it...
2022-09-05 16:00
2712
Week's Top Stories
Most Reposted
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
[Picked up by 313 media titles]
2024-10-25 18:29
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
[Picked up by 300 media titles]
2024-10-25 22:48
2024 Malaysia E-commerce Product Selection Expo Reaches Major Milestone Attracting Leading Brands and Businesses From China
[Picked up by 300 media titles]
2024-10-25 07:00
RuggON Showcases Latest Mining Technology at IMARC 2024
[Picked up by 295 media titles]
2024-10-28 14:32
TotalEnergies ENEOS Completes a 1.8 MWp Floating Solar Photovoltaic System Project, a Second Collaboration with S. Kijchai Enterprise in Thailand
[Picked up by 288 media titles]
2024-10-29 11:24
Most Read
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
2024-10-25 18:29
8605
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
2024-10-25 22:48
7453
Infobip and Singtel Partner to Advance Customer Engagement for Singapore Businesses with Rich Communication Services
2024-10-25 12:30
7037
Global development relies on cooperation
2024-10-25 12:38
6033
Peak Energy CEO Gavin Adda Speaks at Asia Clean Energy Summit 2024
2024-10-25 18:30
5741
